-
1.发明公开公开(公告)号：US20230255963A1
公开(公告)日：2023-08-17
申请号：US18137210
申请日：2023-04-20
IPC分类号： A61K31/4985 , C07D213/80 , C07D231/56 , C07D401/04 , C07D257/04 , C07D211/62 , C07D213/30 , C07C69/76 , C07C65/30 , C07D215/14 , C07D471/04 , C07D487/04 , A61K31/192 , A61K31/235 , A61K31/41 , A61K31/416 , A61K31/437 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/47
CPC分类号： A61K31/4985 , C07D213/80 , C07D231/56 , C07D401/04 , C07D257/04 , C07D211/62 , C07D213/30 , C07C69/76 , C07C65/30 , C07D215/14 , C07D471/04 , C07D487/04 , A61K31/192 , A61K31/235 , A61K31/41 , A61K31/416 , A61K31/437 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/47
摘要： Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
-
公开(公告)号：US11661410B2
公开(公告)日：2023-05-30
申请号：US16639051
申请日：2018-08-13
发明人： Zhe Li , Ming Yu , Qing Xu , Manuel Zancanella
IPC分类号： C07D403/12 , C07D401/14 , C07D405/14 , C07D219/10 , C07D221/06 , C07D401/12 , C07D413/12 , C07D471/04 , C07D471/08 , C07D491/044 , C07D491/056 , A61K31/473 , A61K31/4741 , A61K31/4375 , A61P35/00 , C07D215/42 , C07B59/00 , C07D487/04 , C07D453/02 , C07D487/08
CPC分类号： C07D401/12 , C07B59/002 , C07D215/42 , C07D401/14 , C07D405/14 , C07D413/12 , C07D453/02 , C07D487/04 , C07D487/08 , C07D491/044 , C07D491/056 , C07B2200/05
摘要： The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
-
公开(公告)号：US20230159538A1
公开(公告)日：2023-05-25
申请号：US17916530
申请日：2021-03-31
发明人： Ming Yu , Brian Edwin Cathers , Zhe Li , Brian Walter Metcalf , Lina Q. Setti , Chul Yu , Manuel Zancanella
IPC分类号： C07D487/04 , C07D519/00
CPC分类号： C07D487/04 , C07D519/00
摘要： The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
-
公开(公告)号：US20230159507A1
公开(公告)日：2023-05-25
申请号：US17991448
申请日：2022-11-21
发明人： Zhe Li
IPC分类号： C07D413/06 , A61K31/5377 , A61K31/541 , C07D417/06 , C07D401/06 , C07D211/22 , C07D403/06 , C07D265/30 , A61P7/06
CPC分类号： C07D413/06 , A61K31/5377 , A61K31/541 , C07D417/06 , C07D401/06 , C07D211/22 , C07D403/06 , C07D265/30 , A61P7/06
摘要： The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
-
公开(公告)号：US20230151016A1
公开(公告)日：2023-05-18
申请号：US18155304
申请日：2023-01-17
发明人： Lina Q. Setti , Shahul Nilar , Zhe Li , Ming Yu , Manuel Zancanella
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
-
公开(公告)号：US20220396562A1
公开(公告)日：2022-12-15
申请号：US17242731
申请日：2021-04-28
发明人： Qing Xu , CARSTEN ALT , ZHE LI , SHAHUL NILAR , PETER MICHAEL RADEMACHER , CALVIN WESLEY YEE
IPC分类号： C07D401/14 , C07D471/08 , C07D401/04 , C07D403/04 , C07D413/14 , C07D405/14 , C07D417/14 , C07D498/08 , C07D417/04 , C07D471/04 , C07D491/056 , C07D413/04 , C07D403/14
摘要： The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I′ and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
-
公开(公告)号：US20220324833A1
公开(公告)日：2022-10-13
申请号：US17843283
申请日：2022-06-17
发明人： Fang Wang , Youqian Deng , Morin Mae Frick , Xiang Wang
IPC分类号： C07D401/04
摘要： The present disclosure relates to processes for preparing a compound of Formula (I)
-
公开(公告)号：US11286243B2
公开(公告)日：2022-03-29
申请号：US16712628
申请日：2019-12-12
发明人： Zhe Li , Qing Xu , Brian Walter Metcalf , Calvin Wesley Yee , Peter Michael Rademacher , Carsten Alt
IPC分类号： C07D498/04 , C07D513/04 , C07D277/62 , A61P7/00 , C07D233/96 , A61K45/06
摘要： The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis. The compounds of Formula I and pharmaceutical salts thereof have the following structure: wherein R1, R2, R3, X1, X2, X3, X4, Y1, Y2, and Y3 are as described herein.
-
公开(公告)号：US11236109B2
公开(公告)日：2022-02-01
申请号：US16357148
申请日：2019-03-18
发明人： Zhe Li , Qing Xu , Brian W. Metcalf , Stephen L. Gwaltney, II , Jason R. Harris , Calvin W. Yee
IPC分类号： C07D401/04 , C07D498/08 , C07D491/107 , C07D213/74 , C07D403/04
摘要： Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
-
公开(公告)号：US11111243B2
公开(公告)日：2021-09-07
申请号：US16002408
申请日：2018-06-07
发明人： Chul Yu , Ming Yu , Manuel Zancanella , Zhe Li
IPC分类号： C07D471/04 , A61P7/00 , C07D519/00 , C07D487/04
摘要： The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
-
-
-
-
-
-
-
-
-
搜索结果
151 条记录 (耗时 0.03 秒)
